Matrix Capital Management Company, LP Adaptimmune Therapeutics PLC Transaction History

Matrix Capital Management Company, LP

$2.09 Billion
Q3 2024

A detailed history of Matrix Capital Management Company, LP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Matrix Capital Management Company, LP holds 37,681,515 shares of ADAP stock, worth $24.9 Million. This represents 1.71% of its overall portfolio holdings.

Number of Shares

37,681,515

Previous 38,974,185 3.32%

Holding current value

$24.9 Million

Previous $38.2 Million 6.28%

% of portfolio

1.71%

Previous 0.29%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.39 $1.19 Million - $1.8 Million	-1,292,670 Reduced 3.32%	37,681,515 $35.8 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $11.7 Million - $55 Million	4,545,455 Added 13.2%	38,974,185 $390 Million
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $7.71 Million - $29.1 Million	6,428,730 Added 22.96%	34,428,730 $93.6 Million
Q1 2019 May 15, 2019	BUY	$3.63 - $6.06 $3.09 Million - $5.16 Million	851,000 Added 3.13%	28,000,000 $120 Million
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $25.5 Million - $96.1 Million	6,786,989 Added 33.33%	27,149,000 $156 Million
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $51.9 Million - $85.1 Million	6,278,500 Added 44.58%	20,362,011 $276 Million
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $2.1 Million - $2.77 Million	201,500 Added 1.45%	14,083,511 $167 Million
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $11.8 Million - $19.3 Million	1,668,500 Added 13.66%	13,882,011 $156 Million
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $1.14 Million - $1.49 Million	170,000 Added 1.41%	12,213,511 $81.6 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $59.4 Million - $108 Million	12,043,511	12,043,511 $98.6 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $108M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Matrix Capital Management Company, LP, based on Form 13F filings with the SEC.

News

Stay updated on Matrix Capital Management Company, LP with notifications on news.

Account

Matrix Capital Management Company, LP Adaptimmune Therapeutics PLC Transaction History